Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EchoGen ultrasound contrast agent: Began a Phase III trial in 240 patients who will receive 0.05 ml/kg of the agent, or a saline placebo. The level of contrast

Sonus Pharmaceuticals, Bothell, Wash.
Product: EchoGen ultrasound

Read the full 72 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE